Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schizophrenia | 10 | 2018 | 73 | 2.100 |
Why?
|
| Schizophrenic Psychology | 4 | 2018 | 17 | 0.820 |
Why?
|
| Appetite Depressants | 3 | 2018 | 8 | 0.730 |
Why?
|
| Antipsychotic Agents | 6 | 2013 | 68 | 0.690 |
Why?
|
| Satiation | 1 | 2018 | 8 | 0.650 |
Why?
|
| Oxytocin | 1 | 2018 | 24 | 0.630 |
Why?
|
| Receptor, Cannabinoid, CB1 | 2 | 2013 | 40 | 0.540 |
Why?
|
| Piperidines | 2 | 2013 | 76 | 0.540 |
Why?
|
| Pyrazoles | 2 | 2013 | 80 | 0.530 |
Why?
|
| Periodontal Diseases | 1 | 2014 | 49 | 0.470 |
Why?
|
| Satiety Response | 1 | 2013 | 3 | 0.460 |
Why?
|
| Overweight | 2 | 2013 | 233 | 0.460 |
Why?
|
| Patient Compliance | 1 | 2010 | 202 | 0.350 |
Why?
|
| Double-Blind Method | 5 | 2018 | 269 | 0.350 |
Why?
|
| Brain | 3 | 2018 | 1268 | 0.350 |
Why?
|
| Stress, Psychological | 1 | 2014 | 541 | 0.320 |
Why?
|
| Depression | 1 | 2014 | 664 | 0.310 |
Why?
|
| Exercise | 2 | 2011 | 524 | 0.290 |
Why?
|
| Eating | 2 | 2018 | 152 | 0.250 |
Why?
|
| Middle Aged | 11 | 2018 | 9642 | 0.220 |
Why?
|
| Adult | 11 | 2018 | 11034 | 0.200 |
Why?
|
| Psychotic Disorders | 2 | 2012 | 52 | 0.200 |
Why?
|
| Clozapine | 2 | 2011 | 17 | 0.190 |
Why?
|
| Body Mass Index | 3 | 2013 | 775 | 0.180 |
Why?
|
| Pilot Projects | 4 | 2018 | 628 | 0.170 |
Why?
|
| Receptor, Cholecystokinin B | 1 | 2018 | 9 | 0.170 |
Why?
|
| Central Nervous System Agents | 1 | 2018 | 7 | 0.170 |
Why?
|
| Mental Disorders | 2 | 2013 | 285 | 0.170 |
Why?
|
| Acetamides | 1 | 2018 | 12 | 0.170 |
Why?
|
| Phenylurea Compounds | 1 | 2018 | 18 | 0.170 |
Why?
|
| Male | 12 | 2018 | 18870 | 0.170 |
Why?
|
| Administration, Intranasal | 1 | 2018 | 77 | 0.160 |
Why?
|
| Taste | 1 | 2018 | 36 | 0.160 |
Why?
|
| Female | 12 | 2018 | 19873 | 0.160 |
Why?
|
| Smell | 1 | 2018 | 35 | 0.160 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 102 | 0.160 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2018 | 75 | 0.160 |
Why?
|
| Humans | 14 | 2018 | 34853 | 0.150 |
Why?
|
| Leptin | 1 | 2018 | 115 | 0.150 |
Why?
|
| Insulin | 1 | 2018 | 224 | 0.140 |
Why?
|
| Blood Glucose | 1 | 2018 | 333 | 0.140 |
Why?
|
| Cocaine | 1 | 2018 | 219 | 0.140 |
Why?
|
| Immunity, Humoral | 1 | 2014 | 23 | 0.120 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 68 | 0.120 |
Why?
|
| Body Weight | 2 | 2013 | 404 | 0.120 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2013 | 94 | 0.120 |
Why?
|
| Disease Susceptibility | 1 | 2014 | 92 | 0.120 |
Why?
|
| Drug Inverse Agonism | 1 | 2013 | 2 | 0.120 |
Why?
|
| Time Factors | 1 | 2018 | 1681 | 0.120 |
Why?
|
| Chronic Disease | 2 | 2014 | 469 | 0.110 |
Why?
|
| Diet, Gluten-Free | 1 | 2012 | 2 | 0.110 |
Why?
|
| Gliadin | 1 | 2012 | 3 | 0.110 |
Why?
|
| Transglutaminases | 1 | 2012 | 8 | 0.110 |
Why?
|
| Energy Intake | 1 | 2013 | 160 | 0.110 |
Why?
|
| Antibodies | 1 | 2012 | 135 | 0.110 |
Why?
|
| Disease Progression | 1 | 2014 | 580 | 0.100 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2011 | 3 | 0.100 |
Why?
|
| Benzodiazepines | 1 | 2011 | 13 | 0.100 |
Why?
|
| Propylamines | 1 | 2011 | 6 | 0.100 |
Why?
|
| Pleasure | 1 | 2011 | 4 | 0.100 |
Why?
|
| Marijuana Abuse | 1 | 2012 | 83 | 0.100 |
Why?
|
| Maryland | 4 | 2012 | 53 | 0.100 |
Why?
|
| Affective Symptoms | 1 | 2011 | 55 | 0.090 |
Why?
|
| Organ Size | 1 | 2010 | 148 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2010 | 196 | 0.090 |
Why?
|
| Young Adult | 2 | 2018 | 4012 | 0.090 |
Why?
|
| Health Behavior | 1 | 2014 | 491 | 0.090 |
Why?
|
| Alcoholism | 1 | 2012 | 220 | 0.090 |
Why?
|
| Treatment Outcome | 1 | 2013 | 1349 | 0.080 |
Why?
|
| Adolescent | 1 | 2018 | 5035 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2012 | 243 | 0.070 |
Why?
|
| Signal Transduction | 1 | 2013 | 1802 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 628 | 0.060 |
Why?
|
| Obesity | 1 | 2011 | 965 | 0.060 |
Why?
|
| Smoking | 1 | 2009 | 903 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2012 | 1961 | 0.050 |
Why?
|
| Statistics as Topic | 2 | 2011 | 111 | 0.050 |
Why?
|
| Neuropsychological Tests | 2 | 2011 | 255 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2011 | 528 | 0.040 |
Why?
|
| Raclopride | 1 | 2018 | 7 | 0.040 |
Why?
|
| Comorbidity | 2 | 2012 | 606 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 55 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2018 | 137 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2018 | 79 | 0.040 |
Why?
|
| Cocaine-Related Disorders | 1 | 2018 | 84 | 0.040 |
Why?
|
| Dopamine | 1 | 2018 | 232 | 0.040 |
Why?
|
| Age Factors | 2 | 2010 | 1007 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 984 | 0.030 |
Why?
|
| Risk Factors | 2 | 2012 | 3414 | 0.030 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2011 | 7 | 0.030 |
Why?
|
| Diet, Reducing | 1 | 2011 | 22 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2012 | 322 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 142 | 0.020 |
Why?
|
| Autopsy | 1 | 2010 | 40 | 0.020 |
Why?
|
| Attention | 1 | 2011 | 147 | 0.020 |
Why?
|
| Age Distribution | 1 | 2010 | 223 | 0.020 |
Why?
|
| Risk | 1 | 2009 | 256 | 0.020 |
Why?
|
| Life Style | 1 | 2011 | 288 | 0.020 |
Why?
|
| Psychometrics | 1 | 2011 | 292 | 0.020 |
Why?
|
| Cause of Death | 1 | 2009 | 154 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2009 | 113 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 429 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 423 | 0.020 |
Why?
|
| Aged | 2 | 2010 | 6448 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 517 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 901 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 859 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2010 | 964 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 841 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2010 | 1422 | 0.020 |
Why?
|
| Prevalence | 1 | 2010 | 1425 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2009 | 685 | 0.010 |
Why?
|
| United States | 1 | 2010 | 3894 | 0.010 |
Why?
|